Solid lipid nanoparticle a complete tool for brain targeted drug delivery
DOI:
https://doi.org/10.12923/cipms-2025-0002Keywords:
BBB, solid lipid nanoparticles, CNS drug delivery, delivery challenges, delivery strategiesAbstract
The current review focuses on the potential of solid lipid nanoparticulate systems for effective targeted delivery to the brain. The challenges in delivering the drug to the brain are discussed, as are brain targeting strategies and possible mechanisms. The benefits of using solid lipid nanoparticles as carriers to deliver the drug into the brain are also addressed. Furthermore, the physical and chemical properties of solid lipid nanoparticles are considered with regard to solving the important challenges raised in developing the appropriate brain targeting formulations. The authors conclude that a thorough examination of the technology's potential use concerning the current state of brain medication research is urgently required.
References
1. Topal GR, Mészáros M, Porkoláb G, Szecskó A, Polgár TF, Siklós L, et al. ApoE-Targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood–brain barrier. Pharmaceutics. 2020;13(1):38.
2. Singh G, Sharma M, Kumar GA, Rao NG, Prasad K, Mathur P, et al. The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990-2019. Lancet Glob Health. 2021;9(8):e1129-44.
3. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Controlled Release. 2008;127(2):97-109.
4. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37(1):13-25.
5. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Controlled Release. 2011;152(2):208-31.
6. Kadry H, Noorani B, Cucullo L. A Blood Brain Barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1):69.
7. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2012;64(7):686-700.
8. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010;40(5):385-403.
9. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JEN, Omidfar K. Drug targeting using solid lipid nanoparticles. Chem Phys Lipids. 2014;181:56-61.
10. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59(6):454-77.
11. Anand A, Iyer BR, Ponnusamy C, Pandiyan R, Sugumaran A. Design and development of lomustine loaded chitosan nanoparticles for efficient brain targeting. Cardiovasc Hematol Agents Med Chem. 2020;18(1):45-54.
12. Mahringer A, Puris E, Fricker G. Crossing the blood-brain barrier: A review on drug delivery strategies using colloidal carrier systems. Neurochem Int. 2021;147:105017.
13. Omidi Y, Kianinejad N, Kwon Y, Omidian H. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier. Expert Rev Clin Pharmacol. 2021;14(3):357-81.
14. Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10(7):889-905.
15. Barbu E, Molnàr É, Tsibouklis J, Górecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier. Expert Opin Drug Deliv. 2009;6(6):553-65.
16. Orthmann A, Fichtner I, Zeisig R. Improving the transport of chemotherapeutic drugs across the blood–brain barrier. Expert Rev Clin Pharmacol. 2011;4(4):477-90.
17. Gupta KR, Dabhekar S, Dixit M, Umekar MJ. Nano-carriers for brain disorders targeting the Blood Brain Barrier (BBB) crossing strategies. Indian J Pharm Pharmacol. 2021;7(4):213-21.
18. Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, Radu CI, Grumezescu AM, et al. Current strategies to enhance delivery of drugs across the Blood–Brain Barrier. Pharmaceutics. 2022;14(5):987.
19. Choudhari M, Hejmady S, Narayan Saha R, Damle S, Singhvi G, Alexander A, et al. Evolving new-age strategies to transport therapeutics across the Blood-Brain-Barrier. Int J Pharm. 2021;599:120351.
20. Mura P, Maestrelli F, D’Ambrosio M, Luceri C, Cirri M. Evaluation and comparison of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. Pharmaceutics. 2021;13(4):437.
21. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497-508.
22. Tang Y, Wang X, Li J, Nie Y, Liao G, Yu Y, et al. Overcoming the reticuloendothelial system barrier to drug delivery with a “Don’t-Eat-Us” strategy. ACS Nano. 2019;13(11):13015-26.
23. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
24. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
25. Rouco H, Diaz-Rodriguez P, Remuñán-López C, Landin M. Recent advances in solid lipid nanoparticles formulation and clinical applications. In: Nanomaterials for Clinical Applications. Elsevier; 2020:213-47.
26. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. J Appl Pharm Sci. 2020;10(6):126-41.
27. Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349.
28. Lasa-Saracibar B, Estella-Hermoso de Mendoza A, Guada M, Dios-Vieitez C, Blanco-Prieto MJ. Lipid nanoparticles for cancer therapy: state of the art and future prospects. Expert Opin Drug Deliv. 2012;9(10):1245-61.
29. Duong VA, Nguyen TTL, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020;25(20):4781.
30. Anand A, Sugumaran A, Narayanasamy D. Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles. IET Nanobiotechnol. 2019;13(4):353-62.
31. Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci. 2020;7:587997.
32. Jnaidi R, Almeida AJ, Gonçalves LM. Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme. Pharmaceutics. 2020;12(9):860.
33. Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines. Vaccines. 2021;9(4):359.
34. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification – diffusion technique. Int J Pharm. 2003;257(1-2):153-60.
35. Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777-91.
36. Ochubiojo M, Chinwude I, Ibanga E, Ifianyi S. Nanotechnology in drug delivery. In: A.D. Sezer (ed.). Recent advances in novel drug carrier systems. InTech; 2012.
37. Waghmare AS, Grampurohit ND, Gadhave MV, Gaikwad DD, Jadhav SI. Solid lipid nanoparticles: A promising drug delivery system. Int Res J Pharmacy. 2012;3:100-7.
38. Chandni SV, Viral S, Umesh U. Solid lipid nanoparticles: a review. J Curr Pharma Res. 2011;1(4):351.
39. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125-31.
40. Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 2014;11(4):1239-49.
41. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release Off J Control Release Soc. 2005;108(1):112-20.
42. Chen Y jun, Jin R xian, Zhou Y qin, Zeng J, Zhang H, Feng Q ran. Preparation of solid lipid nanoparticles loaded with Xionggui powder-supercritical carbon dioxide fluid extraction and their evaluation in vitro release. Zhongguo Zhong Yao Za Zhi. 2006;31(5):376-9.
43. Sridhar R, Ramakrishna S. Electrosprayed nanoparticles for drug delivery and pharmaceutical applications. Biomatter. 2013;3(3):e24281.
44. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4):286-96.
45. Priano L, Zara GP, El-Assawy N, Cattaldo S, Muntoni E, Milano E, et al. Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. Eur J Pharm Biopharm. 2011;79(1):135-41.
46. El-Say KM, Hosny KM. Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits. PLOS ONE. 2018;13(8):e0203405.
47. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release Off J Control Release Soc. 2005;107(2):215-28.
48. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-9.
49. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37(3-4):508-13.
50. Potta SG, Minemi S, Nukala RK, Peinado C, Lamprou DA, Urquhart A, et al. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility. J Microencapsul. 2011;28(1):74-81.
51. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech. 2007;8(1):24.
52. Ayan AK, Yenilmez A, Eroglu H. Evaluation of radiolabeled curcumin-loaded solid lipid nanoparticles usage as an imaging agent in liver-spleen scintigraphy. Mater Sci Eng C. 2017;75:663-70.
53. Khan AS, Shah KU, Mohaini MA, Alsalman AJ, Hawaj MAA, Alhashem YN, et al. Tacrolimus-loaded solid lipid nanoparticle gel: Formulation development and in vitro assessment for topical applications. Gels. 2022;8(2):129.
54. Asif AH, Desu PK, Alavala RR, Rao GSNK, Sreeharsha N, Meravanige G. Development, statistical optimization and characterization of fluvastatin loaded solid lipid nanoparticles: A 32 factorial design approach. Pharmaceutics. 2022;14(3):584.
55. Hosny KM, Naveen NR, Kurakula M, Sindi AM, Sabei FY, Fatease AA, et al. Design and development of neomycin sulfate gel loaded with solid lipid nanoparticles for buccal mucosal wound healing. Gels. 2022;8(6):385.
56. Unnisa A, Chettupalli AK, Al Hagbani T, Khalid M, Jandrajupalli SB, Chandolu S, et al. Development of dapagliflozin solid lipid nanoparticles as a novel carrier for oral delivery: Statistical design, optimization, in-vitro and in-vivo characterization, and evaluation. Pharmaceuticals. 2022;15(5):568.
57. Nair A, Shah J, Al-Dhubiab B, Jacob S, Patel S, Venugopala K, et al. Clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation and in vivo studies. Pharmaceutics. 2021;13(4):523.
58. Hasan N, Imran M, Kesharwani P, Khanna K, Karwasra R, Sharma N, et al. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Int J Pharm. 2021;599:120428.
59. Kang JH, Chon J, Kim YI, Lee HJ, Oh DW, Lee HG, et al. Preparation and evaluation of tacrolimus-loaded thermosensitive solid lipid nanoparticles for improved dermal distribution. Int J Nanomedicine. 2019;14:5381-96.
60. Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: Production, characterization and stability. Cham: Springer International Publishing ; 2015:1.
61. Jenning V, Mäder K, Gohla SH. Solid lipid nanoparticles (SLNTM) based on binary mixtures of liquid and solid lipids: a 1H-NMR study. Int J Pharm. 2000;205(1-2):15-21.
62. Blasi P, Schoubben A, Romano GV, Giovagnoli S, Di Michele A, Ricci M. Lipid nanoparticles for brain targeting II. Technological characterization. Colloids Surf B Biointerfaces. 2013;110:130-7.
63. Jenning V, Gohla S. Comparison of wax and glyceride solid lipid nanoparticles (SLN®). Int J Pharm. 2000;196(2):219-22.
64. Swarbrick J, editor. Encyclopedia of pharmaceutical technology. 3rd ed. New York: Informa Healthcare; 2007.
65. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003;92(5):1085-94.
66. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine Nanotechnol Biol Med. 2013;9(4):492-503.
67. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol. 2005;27(2):127.
68. Hu L, Jia Y, WenDing. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharm. 2010;65(8):585-7.
69. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85(4):227–34.
70. Li YZ, Sun X, Gong T, Liu J, Zuo J, Zhang ZR. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res. 2010;27(9):1977-86.
71. Chattopadhyay P, Shekunov B, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev. 2007;59(6):444-53.
72. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Controlled Release. 2010;144(2):233-41.
73. Rudolph C, Schillinger U, Ortiz A, Tabatt K, Plank C, Müller RH, et al. Application of Novel Solid Lipid Nanoparticle (SLN)-Gene vector formulations based on a dimeric HIV-1 TAT-Peptide in vitro and in vivo. Pharm Res. 2004;21(9):1662-9.
74. Zhang PR, Xie Y, Li M. Preparation and characterization of budesonide-loaded solid lipid nanoparticles for pulmonary delivery. J Chin Pharm Sci. 2011;20(4).
75. Videira M, Almeida AJ, Fabra À. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine Nanotechnol Biol Med. 2012;8(7):1208-15.
76. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356(1-2):333-44.
77. Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7-22.
78. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, et al. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419(1-2):329-38.
79. Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. Transfersomes: a novel technique for transdermal drug delivery. J Drug Deliv Ther. 2019;9(1):279-85.
80. Rahiman AB, Krishnan K, Sreelekshimi AS, Arjunk KK. Novasome: A pioneering advancementin vesicular drug delivery. Int J Appl Pharm. 2021;13(1):59-64.
81. Barriga HMG, Holme MN, Stevens MM. Cubosomes: The next generation of smart lipid nanoparticles? Angew Chem Int Ed. 2019;58(10):2958-78.
82. Lv Z, Zhu Y, Li F. DNA Functional nanomaterials for controlled delivery of nucleic acid-based drugs. Front Bioeng Biotechnol. 2021;9:720291.
83. Bummer PM. Physical chemical considerations of lipid-based oral drug delivery – solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst. 2004;21(1):1-20.
84. Yu BT, Sun X, Zhang ZR. Enhanced liver targeting by synthesis ofN 1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res. 2003;26(12):1096-101.
85. Arana L, Bayón-Cordero L, Sarasola L, Berasategi M, Ruiz S, Alkorta I. Solid lipid nanoparticles surface modification modulates cell internalization and improves chemotoxic treatment in an oral carcinoma cell line. Nanomaterials. 2019;9(3):464.
86. Kim DD, Cho HJ, Park JW, Yoon IS. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine. 2014;495.
87. Shen H, Shi S, Zhang Z, Gong T, Sun X. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics. 2015;5(7):755-71.
88. Zhou M, Hou J, Zhong Z, Hao N, Lin Y, Li C. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Deliv. 2018;25(1):716-22.
89. Pandit AA, Dash AK. Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomed. 2011;6(8):1397-412.
90. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from n-trimethyl chitosan surface-modified solid lipid nanoparticles: Pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32(2):389-402.
91. Derakhshandeh K, Kashanian, Hemati Azandaryani A. New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell. Int J Nanomedicine. 2011;6; 2393-2401.
92. Shi LL, Xie H, Lu J, Cao Y, Liu JY, Zhang XX, et al. Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm. 2016;13(8):2667-76.
93. Ramalingam P, Ko YT. Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;139:52-61.
94. Jeon HS, Seo JE, Kim MS, Kang MH, Oh DH, Jeon SO, et al. A retinyl palmitate-loaded solid lipid nanoparticle system: Effect of surface modification with dicetyl phosphate on skin permeation in vitro and anti-wrinkle effect in vivo. Int J Pharm. 2013;452(1-2):311-20.
95. Alexander M, Dalgleish DG. Dynamic light scattering techniques and their applications in food science. Food Biophys. 2006;1(1):2-13.
96. Dale PJ, Kijlstra J, Vincent B. Adsorption of non-ionic surfactants on hydrophobic silica particles and the stability of the corresponding aqueous dispersions. Langmuir ACS J Surf Colloids. 2005;21(26):12250-6.
97. Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314(1):56-62.
98. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul. 2009;26(4):287-96.
99. Kayat J, Gajbhiye V, Tekade RK, Jain NK. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomedicine Nanotechnol Biol Med. 2011;7(1):40-9.
100. Alagusundaram M, Chengaiah B, Gnanaprakash K, Ramkanth S, Chetty CM, Dhachinamoorthi D. Nasal drug delivery system-an overview. Int J Res Pharm Sci. 2010;1(4):454-65.
101. Türker S, Onur E, Ózer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004;26(3):137-42.
102. Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur J Pharm Sci. 2013;48(3):393-405.
103. Abbas H, Refai H, El Sayed N. Superparamagnetic iron oxide – loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of Clonazepam. J Pharm Sci. 2018;107(8):2119-27.
104. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32(12):3340-50.
105. Estella-Hermoso de Mendoza A, Préat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Controlled Release. 2011;156(3):421-6.
106. Sharma P, Dube B, Sawant K. Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia. J Nanosci Nanotechnol. 2011;11(8):6676-82.
107. Kuang Y, Zhang K, Cao Y, Chen X, Wang K, Liu M, et al. Hydrophobic IR-780 dye encapsulated in cRGD-conjugated solid lipid nanoparticles for NIR imaging-guided photothermal therapy. ACS Appl Mater Interfaces. 2017;9(14):12217-26.
108. Becker Peres L, Becker Peres L, de Araújo PHH, Sayer C. Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique. Colloids Surf B Biointerfaces. 2016;140:317-23.
109. Tsou Y, Zhang X, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood–brain barrier using nanomaterials. Small. 2017;13(43):1701921.
110. Rawal SU, Patel BM, Patel MM. New drug delivery systems developed for brain targeting. Drugs. 2022;82(7):749-92.
111. Liu P, Jiang C. Brain‐targeting drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(5).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
